Why the study?
Does on-treatment platelet reactivity predict bleeding events in Japanese ACS patients undergoing PCI on antiplatelet therapy?
Does on-treatment platelet reactivity predict bleeding events in Japanese ACS patients undergoing PCI on antiplatelet therapy?
On-treatment platelet reactivity measured by PRU or VASP-PRI is not associated with bleeding risk in Japanese ACS patients undergoing PCI on prasugrel or clopidogrel.
Does not support platelet reactivity testing to predict bleeding; leaves open whether reactivity-guided dosing improves outcomes in ACS-PCI.
No takes yet. Share an insight, caveat, or question.
Nishikawa et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: